1-4 of 4
Asen Bagashev
Close
Sort by
Journal Articles

Alisertib Synergistically Strengthens the Anti-Leukemia Activity of Venetoclax in TCF3-Hlf B-ALL

Asen Bagashev, Joseph Patrick Loftus, Colin Wakefield, Gerald Wertheim, Christian Hurtz, Martin P. Carroll, Kimberly Stegmaier, Yana Pikman, Sarah K Tasian
Journal: Blood
Blood (2021) 138 (Supplement 1): 705.
https://doi.org/10.1182/blood-2021-148671
Published: 2021
Journal Articles

Precision Co-Targeting of the Thymic Stromal Lymphopoietin Receptor in Childhood CRLF2 -Rearranged Acute Lymphoblastic Leukemia

Asen Bagashev, Joseph Patrick Loftus, Savannah Ross, Lisa M Niswander, Haiying Qin, Terry J. Fry, Sarah K Tasian
Journal: Blood
Blood (2021) 138 (Supplement 1): 1705.
https://doi.org/10.1182/blood-2021-148602
Published: 2021
Journal Articles

Multi-Modal Targeting of FLT3 with Chimeric Antigen Receptor T Cell Immunotherapy and Tyrosine Kinase Inhibition in High-Risk Pediatric Leukemias

Lisa M Niswander, Zachary Graff, Asen Bagashev, Lillie Leach, Terry J. Fry, Sarah K Tasian
Journal: Blood
Blood (2021) 138 (Supplement 1): 404.
https://doi.org/10.1182/blood-2021-147321
Published: 2021
Journal Articles

The Importance of CD19 Exon 2 for Surface Localization: Closing the Ig-like Loop

Asen Bagashev, PhD, Elena Sotillo, PhD, Glendon Wu, Andrei Thomas-Tikhonenko, PhD
Journal: Blood
Blood (2015) 126 (23): 3433.
https://doi.org/10.1182/blood.V126.23.3433.3433
Published: 2015